Publication: 2071

NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status
      QxMD      Google Scholar   
Citation:
J Thorac Oncol vol 9 (8) 1146-1153
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
424  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10 CA035267, U10 CA035269, CA-37404, CA-35090, U10 CA037404, U10 CA180821, U10 CA063848, CA-35103, CA-25224, CA-35113, UG1 CA189823, U10 CA035113, CA-63848, U10 CA035415, U10 CA063849, U10 CA180882, CA-35415, CA-35269, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
NCCTG-N0821
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Non-small cell lung cancer, Elderly, Nonsquamous histology, Bevacizumab, Survival